Agilent Technologies Inc vs Monster Beverage Corp — how do they compare? Agilent Technologies Inc trades at $149.35 (market cap $42.00B), while Monster Beverage Corp trades at $45.6 (market cap $89.56B). The key difference: Monster Beverage Corp is far larger — about 2.1× Agilent Technologies Inc's market cap, and Agilent Technologies Inc pays a 0.69% dividend while Monster Beverage Corp pays none. Which is the better fit depends on your goals.
| A | MNST | |
|---|---|---|
Market Cap | $42.00B | $89.56B |
Sector | Health | Consumer Staples |
52-Week High | $157.20 | $49.97 |
52-Week Low | $110.24 | $30.86 |
Enterprise Value | $43.55B | $87.85B |
Dividend Yield | 0.69% | — |
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $145.97, up 3.28% in the last session, with a bullish technical outlook from moving averages but overbought RSI levels. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.49, and maintains solid profitability with a net income margin of 19.55%. Recent developments include FDA and EU approvals for diagnostic assays and the acquisition of Biocare Medical, enhancing its healthcare portfolio.
The stock offers upside to the consensus price target of $154.90, supported by analyst optimism (77.5% buy ratings), but high valuation ratios like a P/E of 146.56 pose risks. Investors should monitor execution of growth initiatives and competitive pressures in the life sciences sector, with earnings on August 26, 2026, as a key catalyst.
Monster Beverage (MNST) trades at $45.18, down 4.04% in the last 24 hours, with a bearish technical signal. The company reported strong Q2 2026 earnings, beating estimates with $0.60 EPS and record sales of $2.54 billion, driven by international growth. Financials show robust revenue growth from $8.29 billion in 2025 to a projected $9.2 billion in 2026, with net income margins above 23%. A 2-for-1 stock split is scheduled for August 11, 2026.
Outlook remains positive due to consistent earnings beats and global expansion, but high valuation ratios like a P/E of 41.83 pose risks. Analyst consensus is bullish with a $51.14 price target, though competition and economic sensitivity could pressure margins. Investors should weigh growth potential against premium valuation.
Trailing returns across standard periods
Latest headlines on both assets
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →